Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins

International Journal of Surgical Pathology

Volumn 8, Issue 2, 2000, Pages 133-144

  Panizo Santos, Angel ^a   Sola, Iosu ^a   Vega, Francisco ^a   De Alava, Enrique ^a   Lozano, María Dolores ^a   Idoate, Miguel Angel ^a   Pardo Mindán, Javier ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Gastrointestinal stromal tumors; Immunohistochemistry; Oncoproteins; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; REGULATOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MITOSIS; NECROSIS; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; TUMOR VOLUME;

EID: 0034049784     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690000800208     Document Type: Article

References (39)

1. Amin MB, Chan KMA, Linden MD, Kubus JJ, Zarbo RJ. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Correlation with mitotic count and clinical outcome. Am J Clin Pathol 100:428-432, 1993
2. Ueyama T, Guo KJ, Hashimoto H, Daimam Y, Enjoji M. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 69:947-955, 1992
3. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 103:41-47, 1995
4. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 56:2242-2250, 1985
5. Appelman HD. Smooth muscle tumors of the gastrointestinal tract: What we know now that Stout didn't know. Am J Surg Pathol 10:83-99, 1986
6. England JM. Discriminant functions. Blood Cells 15:463-471, 1989
7. McGrath PC, Neifeld JP, Lawrence W, Kay S, Horsley JS, Parker GA. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 206:706-710, 1987
8. Ray R, Tahan SR, Andrews C, Goldman H. Stromal tumors of the stomach. Prognostic value of the PCNA index. Mod Pathol 7:26-30, 1994
9. Goldblum JR, Appelman HD. Stromal tumors of the duodenum. A histologic and immunohistochemical study of 20 cases. Am J Surg Pathol 19:71-80, 1995
10. Hiruki T, Wolber RA, Owen DA. Proliferating cell nuclear antigen is not a useful prognostic indicator for gastrointestinal stromal tumors (abstract). Mod Pathol 6:47A, 1993
11. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: A pathologic analysis of 100 cases. Cancer 39:255-262, 1977
12. Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O'Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumors: Role of clinical and histological evaluation, flow cytometry, and image cytometry. Am J Surg Pathol 17:588-594, 1993
13. Sbaschnig RJ, Cunningham RE, Sobin LH, O'Leary TJ. Proliferating-cell nuclear antigen immunohistochemistry in the evaluation of gastrointestinal smooth-muscle tumors. Mod Pathol 7:780-783, 1994
14. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody ki-67. J Immunol 133:1710-1715, 1984
15. Gerdes J, Schwab V, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983
16. Yu CC, Fletcher CD, Newman PL, Goodlad A, Burton JC, Levison DA. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumors. J Pathol 166:147-152, 1992
17. Franquemont DW, Frierson HF Jr. Proliferating cell nuclear antigen immunoreactivity and prognosis of gastrointestinal stromal tumors. Mod Pathol 8:473-477, 1995
18. Yuki M, Yokota K, Okuyama S. Cell proliferation and cell death (apoptosis) as indices differentiating malignant from benign gastrointestinal myogenic tumors. Nippon Shokakibyo Gakkai Zasshi 92:206-216, 1995
19. Carrillo R, Candia A, Rodríguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 28:160-165, 1997
20. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462, 1995
21. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994
22. Andreassen A, Oyjord T, Hoving E, Holm R, Florense VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen AL, Fodstad O. P53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468-471, 1993
23. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K, Yandell DW. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199, 1992
24. Leach FS, Tokino T, Meltzer P, Burrel M, Oliner JD, Smith S, Hill D, Sidransky D, Kinzler KW, Vogelstein B. p53 mutations and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234, 1993
25. Cordón-Cardó C, Latres E, Drobnjak M, Oliva MR, Pollak D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ. Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799, 1994
26. Mousses S, McAuley L, Bell RS, Kandel R, Andrulis IL. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9:1-6, 1996
27. Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohasi S, Inoue H, Fukama H. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer 73:2499-2505, 1994
28. Sharma S, Gansler T, Cohen C, DeRose P, Abbott K, Hunter S, Fritsch C, Gramlich T. MDM2 gene amplification and p53 expression in gastrointestinal stromal tumors (abstract). Lab Invest 70:67A, 1994
29. Cai J, Jiang Y, Zhang Y, Lu G, Zhang X, Gao Q, Zuo L. Quantitation of p53 protein expression in gastrointestinal smooth muscle tumors. Clinicopathological correlation and prognostic significance. Chin Med J Engl 108:669-673, 1995
30. Korkolopoulou P, Oates J, Crocker J, Edwards C. p53 expression in oat and non-oat small cell lung carcinomas: Correlations with proliferating cell nuclear antigen. J Clin Pathol 46:1093-1096, 1993
31. Jensen V, Hoyer M, Sorensen FB, Keller J, Jensen OM. MIB-1 expression and iododeoxyuridine labeling in soft tissue sarcomas: An immunohistochemical study including correlations with p53, bcl-2 and histological characteristics. Histopathology 28:437-444, 1996
32. Barrios C, Castresana JS, Ruiz J, Kreicbergs A. Amplification of the c-myc proto-oncogene in soft tissue sarcomas. Oncology 51:13-17, 1994
33. Jeffers MD, Richmond JA, Macaulay EM. Overexpression of the c-myc proto-oncogene occurs frequently in uterine sarcomas. Mod Pathol 8:701-704, 1995
34. Barrios C, Cistercian JS, Kreicbergs A. Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol 17:273-276, 1994
35. Posl M, Amling M, Werner M, Basler I, Salzer-Kuntschik M, Winkler K, Delling G. Osteosarcoma: Apoptosis and proliferation. Study of bcl-2 expression. Pathologe 15:337-344, 1994
36. Chiolsi M, Facchetti F, Deitos AP, Lestani M, Morassi ML, Martignoni G, Sorio C, Benedetti A, Morelli L, Doglioni C, Barberis M, Menestrina F, Viale G. Bcl-2 expression in pleural and extrapleural solitary fibrous tumors. J Pathol 181:362-367, 1997
37. Hunter T. Cooperation between oncogenes. Cell 64:249-270, 1991
38. Núñez G, Seto M, Seremetis S, Ferero D, Grignani F, Korsmeyer SJ, Dalla-Favera R. Growth and tumor promoting effects of deregulated bcl-2 in human B lymphoblastoid cells. Proc Nab Acad Sci USA 86:4589-4593, 1989
39. Bissonnette RP, Echeverri F, Mahboubi AD, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 8:552-554, 1992